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6.1 Introduction
Nowadays, symptomatic therapy such as
surgical operation and drug therapy are given to
patients. Medification is regularly done by oral
administration, and intramuscular and venous
injection. Injection usually causes pain and tissue
injury, and it is difficult to give oral administration
based on individual differences such as sex, age
and disease condition. The administered drug
distributes not only to the affected site but also to
the normal cells (tissue), and decreases due to
hepatic metabolism. Thus, only small part of the
administered dosage reaches and acts on the
affected site, and the drug distributed to the
normal cells may cause adverse reactions. So, one
administration or injection of the drug cannot
maintain an effective concentration in the blood
over many hours, causing a repeated dosage with
more than the necessary dosage.
In recent years, as a measure to conduct safer
and more effective drug treatment by inhibiting
excessive drug use and adverse reactions,
researches on a drug delivery system (DDS) that
aims to supply the necessary minimum drug to
the necessary site at the necessary time, are in the
active.The DDS has two types of methods; one is a
method to dissolve a drug slowly in the living
body, and the other is a method to deliver a drug
to the affected target site through the blood flow.
To achieve the practical use of these methods,
only the modification of drug is not enough. It is
in need to develop matrix materials such as
polymer materials or ceramic materials as carrier
of drug. In the case of drug carried to the
capillaries in the affected site through blood flow,
the drug particle size including the drug and
matrix material must be several nm to 200 nm (1
nm = 1/1 billion m) at maximum[1] because the
diameter of the capillary is approximately 5mm
and the absorbency of the drug increases with the
decrease in the particle size of the drug.
For the treatment of cancer and regenerative
medicine, utilization of polymer micelle and
liposome as drug carrier shows a significant
advancement, leading to a number of clinical
studies. For bio-diagnosis/treatment and DDS in
the gastrointestinal system, a practical MEMS was
developed. At present, research and development
of DDS has begun to bear fruit like this. Moreover,
the research and development of DDS was taken
up in the “Development and Application of
Advanced Science Technology” (Nanomedicine
Project) in the science technology policy of the
Ministry of Health, Labour and Welfare in 2002,
that is one example showing that it reached a
breakthrough stage.
Therefore, in this report, we will introduce the
present status of the research and development of
DDS, prospect the future picture of DDS, and
discuss the necessities of research and
development on it, and arrangement of a research
system.
6.2 Efficacy of DDS
From the standpoint of treatment and
pharmaceutical development, the following
efficacies are expected from the DDS technique[2].
(1) It is possible to take out only a particular
action and to suppress the onset of a
particular action. (Separation of actions)
(2) The efficacy becomes more exact. Reduction
of the dosage and extension of the
applicability of drug can be expected.
(Increase of efficacy)
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(3) A dropped out compound due to adverse
reactions can be revived as a drug. (Reduction
of adverse reactions, increase of safety)
(4) The burden on medical staff and patients can
be reduced.The problem of no time to spare
can be resolved. (Improvement of the
convenience in use)
(5) Extension of the life cycle of products and
reduction of medical expenses become
available. (Economy)
In the research and development of DDS,
according to the deeper understanding of the bio-
mechanism and the advancement of material
design technology, DDS is expected to provide
more effective and safer treatment also in new
therapies such as gene therapy and regenerative
medicine, as well as in the use of genome
products.
6.3 DDS to date
Various DDSs are considered as shown in Figure
1[3], and several DDSs have reached the stage of
practical use. The material to carry the drug is of
importance in considering DDS, and particularly in
the administration via blood, the material to carry
the drug requires the following properties.
(1) A large drug volume with a small particle size
(100 nm).
(2) High water solubility.
(3) High stability of the structure.
(4) Ability of biodecomposition and bioabsorp-
tion after playing a role.
Polymer and ceramic materials having the above
properties were developed, and, to date, the
following DDSs have been put into practical use. If
DDSs are roughly divided into two categories, one
is the slow release of drug at a certain rate in a
certain period of time (sustained release of drug),
and the other is targeting of drug by selectively
transporting the drug to the affected target site
(targeting of drug).
(1) Sustained release of drug
The purpose of the sustained release of drug is
to keep a certain concentration of the drug in the
blood over a long term. As basic principles of the
sustained release of drug, there are a reservoir
type and a monolithic type as shown in Figure 2.
The reservoir type uses a method to control the
amount of permeated drug by utilizing the
permeability of the polymer membrane covering
the drug. The monolithic type uses a method to
control the diffusion of drug by dispersing the
drug into a polymer or ceramic matrix.
When the drug is administered by a normal
method, the concentration of drug in the blood
shows a serrate-shaped change depending on the
time and the number of administration, as shown
in Figure 3. Immediately after administration
concentration of drug rapidly increases, and
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Source: Nikkei Homepage (http://www.nikkei4946.com/today/0105/12.html) 
Figure 1: Mechanism of various DDSs 
occasionally the concentration may reach a certain
level with the risk of adverse drug reaction.
Meanwhile, the drug in blood is metabolized in
the tissues, and the concentration decreases by
excretion, etc. If drug concentration becomes
lower than the necessary minimum, therapeutic
efficacy cannot be obtained at all[4].
T. Higuchi (Utah University), A. Zaffaroni (Alza
Corp.) and others enclosed a drug for glaucoma
(Pilocarpine) in ethylene-vinyl acetate copolymer
(EVA) to be worn like contact lenses.As a result, an
Ocusert system, which sustained the efficacy of
the drug for 4-7 days, was put into practical use in
1974, and the product was launched in Japan in
1981.The annual sales of the system is more than
60 billion yen worldwide. In addition, as
transdermal therapeutic systems (TTS) using PEVA
membrane to control the absorption of drug
through the skin just like patches, an antiangina
drug Nitroglycerin and antihypertensive drug
Clonidine (Catapres-TTS) were put into practical
use in 1989. Recently, a TTS (Nicotinell-TTS) to
assist smoking cessation was also put into
practical use in 1998. This type of DDS has the
advantage that it can be easily discontinued when
a problem such as adverse reaction occurs. This
advantage assisted the rapid progress to a practical
use.
In 1992, for prostatic cancer, Takeda Chemical
Industries, Ltd. put a drug named Ryuprin into
practical use, which allows the retention of blood
drug concentration for 4 weeks. It has been used
in more than 70 countries across the world, and
annual sales reached more than 150 billion yen. In
addition, Ryuprin SR Injection Kit 11.25, which
allows the retention of blood drug concentration
for 12 weeks by changing the material enclosing a
drug, was put into practical use in August 2002[5].
Diabetes patients must receive insulin injections
several times every day. However, in 1953, Novo
Nordisk A/S mixed two types of insulin crystals,
i.e., easily soluble and hardly soluble, making it
possible to decrease the number of injections to
once daily. If insulin is administered excessively or
blood glucose concentration decreases too much,
it may lead to a life-threatening condition
(hypoglycemia) such as cerebral function disorder,
so it is necessary to conduct insulin treatment at
an appropriate dose according to the glucose
concentration. Therefore, research and develop-
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Figure 2: Basic mechanism of the sustained release of
drug
Figure 4: Ocusert System (treatment for glaucoma)
Figure 3: Temporal change of blood drug concentration
ment activities are being conducted on a material
and system to release insulin according to the
blood glucose concentration, but the system have
not been put into practical use as yet [4].
(2) Drug targeting
The targeting of drug is also called missile
therapy, and it is a method of carrying a drug
effectively to the targeted inflammatory site or
cancer cells to demonstrate the drug’s action. In
1988, Yutaka Mizushima (DDS Research Institute,
Jikei University) developed a lipo product with
particles (liposome) enclosing drugs within an
artificial phospholipid membrane with multiple
layers.This attracted people’s attention as the first
targeting product in the world. The lipo product
utilizes the characteristics in which lipid particles
often gather at the vessel having arteriosclerosis or
at the inflammatory site. Lipo prostaglandin E1
(PGE1) products (first generation) enclosing
PGE1, which is very effective for arteriosclerosis in
lipid particles, was put into practical use. From
1992 to more recent years, annual sales in Japan of
approximately 35 billion yen has been maintained.
In PGE1 products, the drug is enclosed in soybean
oil, and the surface is capsuled with lecithin.
Except for the above products, steroid hormones
and non-steroid analgesic/inf lammatory drugs
were put into practical use. At present, for the
second-generation PGE1 product produced by
esterifying PGE1, Mitsubishi Pharma Corporation
is conducting phase 2 and phase 3 of the clinical
studies in the United States and Japan[6].
On the other hand, research and development
activities on drugs targeting cancer cells have
been conducted based on a principle of active
targeting to accumulate the anticancer drug to
cancer, utilizing the antigen-antibody reaction with
cancer cells.A certain level of achievement in the
laboratory was obtained, but no success in animal
tests has been obtained.The reason is because an
antigen similar to the target cancer antigen exists
in the blood and on the surface of other normal
cells, and, therefore, the necessary amount of drug
cannot be concentrated onto the target site.
Since Hiroshi Maeda (Dept. of Medical
Researches, Kumamoto University Graduate
School) et al. advocated the enhanced permeation
and retention (EPR) effect in 1986, research on the
targeting to solid cancer has significantly changed.
As shown in Figure 5, new blood vessels in cancer
tissue have a higher permeability than blood
vessels in normal tissue, so that more polymer
compound with a large molecular size permeates
and transfers into cancer tissue. In addition, the
recovery mechanism of polymer compounds
through lymph vessels is incomplete in cancer
tissue, so retention of a polymer compound within
the cancer tissue may easily occur [7].This is called
an EPR effect. By this effect, passive targeting to
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Figure 5: Selective delivery of anticancer drug to the site of solid cancer (EPR effect)
have cancer cells take in a drug in the blood
became possible.As a result, in 1986 and after, the
targeting to solid cancer made a new start as
passive targeting by inhibiting the metabolism in
the liver and kidney and using the sustained
release, in contrast to the conventional active
targeting by the antigen-antibody reaction.
6.4 Current status of research
and development of DDS
As stated above, the research and development
of DDS to date may be roughly divided into two;
sustained release of drug and targeting to the
affected target site, and these are considered
individually. However, after the EPR effect was
advocated for the targeting of solid cancer, the
research and development came to be conducted
not only for targeting to cancer cells but also for
the system associated with the sustained release
function.
6.4.1  Status of research and development of
DDS in Japan
(1) Targeting to cancer cells
Kazunori Kataoka (Graduate School of
Engineering, University of Tokyo, and the
Biomaterials Center of National Institute for
Materials Science, Japan) et al. obtained a
significant increase in anticancer activity in the
living body using polymer micelle enclosing an
anticancer drug (Adriamycin), and confirmed the
accumulation with a high selectivity to cancer
tissue. As shown in Figure 6, in their study of a
block copolymer using polyethylene glycol in
chain A and poly (aspartic acid) in chain B,
Adriamycin was chemically bound to the part of
chain B to form polymer micelle (aggregate) of
several dozen-nm uniform particle size with chain
A as the outer core, and Adriamycin was also
adsorbed physically to the inner core.
When aqueous solution containing polymer
micelle capsuling Adriamycin was administered in
mice with transplanted human colon cancer cells,
the degree of accumulation of Adriamycin in
cancer cells was more than 10 times higher than
in single agent treatment with Adriamycin owing
to the EPR effect, and a high anticancer effect was
confirmed. Currently, phase 1 of the clinical study
is in progress, and the micelle is highly expected
as a targeting DDS to solid cancer. Moreover, the
system of polymer micelle is really a general-
purposed system that is easily applicable to
cisplatin and other anticancer drug hardly soluble
in water. The system is being studied to apply to
gene therapy in which gene-encoding protein for
treatment is enclosed in the micelle and carried
effectively into the target cell.
(2) Application to regenerative medicine
Except for blood cells, most cells adhere to the
scaffolding material, i.e. extracellular matrix, for
proliferation and differentiation in the living body.
When the tissue has a large defect, the scaffold is
also lost. In this case, even if only cells are
supplemented to the defect site, regeneration of
the tissue cannot be expected. In order to
regenerate the tissue, a tentative scaffold of cells
must be supplied to the defect site, and, at the
same time, a cell growth factor to proliferate the
cells must be used. However, the cell growth
factor is protein, and the life span in the living
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Figure 6: Macromolecular micelle containing drug
body is short and unstable. To solve these
problems, if the cell growth factor or the related
gene is capsuled in a bioabsorbent material to
sustain the release in the regenerated site, it is
considered that regeneration of the tissue will
accelerate. Researches of regenerative medicine
using DDS are being conducted actively, and here
we introduce a part of them.
[1] Sustained release of cell growth factor using
bioabsorbent polymer hydrogel
This is a technique to prepare hydrogel by cross-
linking gelatin or collagen, or polymer mixtures
such as hyaluronic acid and alginic acid, and fix
the aqueous solution of cell growth factor within
freeze-dried polymer hydrogel. The hydrogel is
decomposed over time in the living body, and the
decomposition rate can be controlled by the
degree of the cross-linking of hydrogel.
Yasuhiko Tabata (Institute for Frontier Medical
Sciences, Kyoto University) et al. are conducting a
study of sustained release of cell growth factor
utilizing the bioabsorbent gelatin hydrogel with
less toxicity in the living body.They consider that
neovascularization can be induced by sustained
release of basic fibroblast growth factor (bFGF),
which is one of the angiogenesis factors, from
gelatin hydrogel. In order to attempt regeneration
of the coronary artery in the heart, at one week
after the furcation of the left anterior descending
artery was ligated in dogs, bFGF impregnated
gelatin hydrogel particles were administered. As
59
Q U A R T E R L Y  R E V I E W  N o . 7  /  A p r i l  2 0 0 3
Figure 8: Sustained release system using inorganic materials
Figure 7: Effect of bFGF impregnated gelatin particles on coronary arteries in the heart
Source: Department of Biomaterials, Department of Molecular Interaction and Tissue
Engineering, Institute For Frontier Medical Sciences, Kyoto University;
homepage of Tabata Laboratory: http://www.frontier.kyoto-u.ac.jp/te02/studies/
research/heart.html 
shown in Figure 7 [8], at one week after treatment,
the blood flow resumed within the cardiac muscle
and neovascularization was confirmed. This
technique is a very useful method to supply
oxygen and nutrition to ischemic disease or
transplant cells, and to maintain the functions. [9]
[2] Sustained release of cell growth factor using
bioabsorbent ceramic material
Yutaka Mizushima, Junzo Tanaka (Biomaterials
Center, National Institute for Materials Science,
Japan) and others are conducting the develop-
ment of carrier materials for regenerative
medicine using materials existing in hard tissues in
the living body such as calcium phosphate and
calcium carbonate. These materials are
characterized in that the carrier is dissolved in the
living body after sustained release of drug and
shows no toxicity within the living body after
being dissolved. In a product using calcium
carbonate, sustained release of steroid hormones
and basic protein was successfully achieved.
In recent years, they have developed the drug
sustained release technique (plug up the pore of
material) for apatite porous particles (pore
diameter, 1-10 mm) existing in the hard tissue
(particularly, bones) in the living body.As shown in
Figure 8, in this system, after a drug is enclosed in
the pore of calcium phosphate particles, the
surface and inner pores are closed using a material
without biotoxicity such as polysaccharides and
calcium carbonate to increase the sustained
release. This can be applied to regenerative
treatment such as subcutaneous and intramuscular
sustained release of protein products, local
treatment, and local retentive sustained release.
Two-week sustained release was successful in
erythropoietin to increase red blood corpuscle,
and in brain neurotropic factor essential for the
survival of neuron of corpus striatum in the brain.
These products were produced by focusing on the
good adsorption of protein by calcium phosphate.
Application to many protein products are
expected after this.
(3) Application to gene therapy
In gene therapy, detoxicated viruses are
currently used as the transgenic agent (vector) in
many cases. However, occasionally it is difficult to
completely eliminate the toxicity of the virus, or
the virus may mutate later causing to obtain
toxicity. Due to such problems, research and
development activities on non-virus transgenic
agents are conducted.
Kazunori Kataoka et al. are conducting the
development of a non-virus transgenic agent in
which a polymer compound mainly consisting
with polyethylene glycol which has biocompatibi-
lity, covers around calcium phosphate taking in
the gene. If this is mixed with human culture cells,
the transgenic agent will be spontaneously taken
into the cells. In cells with low calcium concentra-
tion, calcium phosphate will dissolve and the gene
is expected to be released. In vitro experiments
revealed that the transgenic agent could introduce
a gene into cells and exhibited no toxicity to the
cells. Following this, they plan to start experiments
using animals such as mice.
Masahito Nakanishi (Gene Function Research
Laboratory, National Institute of Advanced
Industrial Science and Technology) et al. are
aiming to develop a new transgenic system
necessary for human gene therapy by membrane-
fusion- liposome utilizing the membrane fusion
activity of Sendai virus.The Sendai virus prolongs
a very stable infection without killing the host
cells. The membrane-fusion-liposome prepared
using the Sendai virus has the outer membrane
originating from the Sendai virus, so that it is
directly fused with cell membrane, and can
transport the inner substance to the objective cell.
(4) Drug targeting by MEMS
As for drug targeting using micro-electro-
mechanical systems (MEMS), a capsule-type
endoscope for the gastrointestinal system without
batteries “NORIKA v3” [10], was announced in the
autumn of 2002 by RF System Lab. (Japan), a
medical camera manufacturer, with a catch phrase
“A robot submarine enters the living body to give
diagnosis and treatment,” as shown in Figure 9.
NORIKA v3 has a built-in electr ic power
generating magnetic coil and electriccondensor in
a 9f~23mm capsule, and can be driven and
controlled from outside of the patient’s body using
electromagnetic waves. By employing a CCD
device for the imaging sensor, and by combining
white and infrared lights and additional light with
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a different wavelength, high-quality moving
pictures just like home videos are able to be
obtained. The capsule has two tanks sharing 40%
of the total volume which is for the administration
of drug solution at the desired position by an
exclusive valve control, that enables it to function
as a DDS in the gastrointestinal system. As for the
prices of NORIKA v3, the capsule will be launched
at 100 U.S. dollars, with the extracorporeal control
device at around 10,000 dollars. In December
2002, samples will be shipped for clinical studies.
On the other hand, for the cardiovascular
system, because the size of the MEMS must be
several hundred nm, the diameter of the capillary
is as small as 5mm. It would be dif ficult to
manufacture MEMS of such size even though
current nanotechnology is utilized. Therefore,
modification of liposome and polymer micelle
with the nanomachine utilizing the morphological
change of the nano-structure molecules are
conducted to obtain a drug targeting nano-
machine. In this case, the valve for control release
of drug is intend to open and close utilizing the
molecular morphological change.
6.4.2  Status of research and development of
DDS in the United States and Europe
Research and development of DDS was also
actively conducted in the United States and
Europe as well as in Japan, aiming for application
in cancer therapy, gene therapy, regenerative
medicine, and AIDS therapy. Also in these
countries, the employed polymer structures are
micelle, dendrimer (dendriform structure), and
liposome, etc. These polymer structures are
characterized in that they can carry larger amount
of drugs than other structures. The combinations
of the polymer structure and drug are varied
according to the employed methods; targeting to
the affected site and sustained release of drug. As
an example, the following may be given[11].
(1) Targeting to cancer cells
• R. Duncan (Cardiff Univ.) et al. in U.K. develop-
ed an anticancer drug for solid cancer and
metastatic cancer tissue. An anticancer drug is
bound to polyethylene glycol and N-(2-
hydroxypropyl) metacryl (hydrophilic polymer
by peptide bond) by peptide bond, which
allows this to circulate in the blood for 24
hours.
• James R. Baker Jr. (Univ. of Michigan) and Jean
M.J. Frechet (Univ. of California, Berkeley) et al.
in the United States have already evaluated the
use of an anticancer drug such as cisplatin and
methotrexate bound to dendrimer (dendriform
structure). The dendrimer is considered to
reach the tissue easier owing to its small
particle size of several nm.
• Glen S. Kwon (Univ. of Wisconsin) et al. in the
United States evaluated an anti-AIDS agent,
amphotericin B combining with micelle of
polyethylene glycol-poly (L-amide asparate)
with 30-50 nm in diameter for the use in AIDS
therapy.
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Figure 9: MEMS for the gastrointestinal system
Source: Homepage of RF-System Lab., http:// WWW.RFNORIKA.comindex1.html
(2) Application to regenerative medicine
• Jeffrey A. Hubbell (Swiss Federal Institute of
Technology, ETH) et al. evaluated the
application of material such as fibrin whose
structure turns to gel from liquid in the living
body to regenerative treatment such as
neovascularization, bone regeneration, and
nerve regeneration. Cell growth factors (VEGF,
etc.) are taken into the material.
(3) Application to gene medicine
• Alexander T. Florence (Univ. of London) et al. in
U.K. developed a dendrimer aggregate
(complex) such as dendrisome and dendriplex
to bind with DNA, and attempted the
application as a transgenic agent.
(4) Drug targeting MEMS
• Given Image Inc. in Israel published the
development of a battery-driving capsule
camera “M2A” in May 2002. However, several
problems were pointed out including picture
resolution, battery life span, retention of the
capsule in the living body, and the sufferings of
the battery’s chemical substances, and it was
reported that it would take several years to
resolve such issues.
As stated above, research and development of
DDS were also conducted extensively and actively
in the United States and Europe. As a general
evaluation of the research and development of
DDS in Japan, in the 1950s when the concept of
DDS was born, development of new
pharmaceutical was highly evaluated but DDS was
not appropriately evaluated.Therefore, the level of
research and development of DDS was behind the
United States and Europe. However, in the 1980s
and after, when the new DDS gained general
appreciation, the study of DDS significantly
increased and achieved the present level in Japan
not inferior to that of the United States and
Europe but likely equivalent or superior to their
level.
6.5 Measures taken by the 
government
From the 1980s to 1990s, research and
development activities of DDS were covered
mainly by the Grant-in-Aid for Scientific Research
of the Ministry of Education. For 6 years from
1982, research and development activities on
materials for DDS were conducted with the grant
for special research (Teiji Tsuruta, professor
emeritus of the University of Tokyo), etc. In
addition, for 3 years from 1999, “Biomolecular
design for biotargeting” in “Research of special
area (A)” (Takeshi Kobayashi, representative of the
Area and belonging to the Graduate School of
Engineering, Nagoya University) was conducted
and the targeting function was examined from a
chemical point of view and the DDS was
reconstructed using engineering knowledge.
It was taken up in the research project
“Development and the application of the
advanced science and technology (Nanomedicine
project to apply nanotech to medicine)” of the
science and technology policy by the Ministry of
Health, Labour and Welfare in 2002.As application
of nanotechnology to the medical field, DDS
development is advanced by the understanding of
diseases such as cardiovascular disease and of the
function of cell receptors. As application of
nanodevice to the medical field, the research and
development of small precision therapeutic
instruments are advanced. Those are important
from the viewpoint of reinforcement of
international competitiveness.
In the Japan Science and Technology
Corporation, in the research area “Invention of
new materials for chemical and biological
systems” of the Core Research for Evaluational
Science and Technology (CREST), as part of
“Aiming to invent chemical and biological
innovative functional materials, molecular
machine, biodevice, biosensor technique in the
nano scale” (Masuo Aizawa, research supervisor
and belonging to the Tokyo Institute of
Technology), “Invention of nano-structure device
functioning as a gene vector” was proposed and
taken up by Kazunori Kataoka et al. in 2001. The
purpose is to create a safe and high-function “gene
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vector” carrying various drugs including gene to
targeted tissue in the living body, and conducting
treatment and diagnosis.The vector is prepared by
the exact self-organization of polymers and lipid
molecules.
In addition, in 2002, the proposal of Tokuko
Haraguchi (Communications Research Laboratory)
et al. concerning the “Invention of artificial cell
nucleus as a gene delivery system” was taken up in
the “Construction and utilization of advanced
function structures of soft nanomachine”
(Hirokazu Hotani, research supervisor and
belonging to the Graduate School of Science,
Nagoya University).The research aims to develop a
gene delivery system with a special function
useful for gene therapy and drug treatment.
Beforehand, understanding of the formation
mechanism of the nuclear membrane around the
chromosome and development of an artificial cell
nucleus with a special function  are conducted.
In the National Institute for Materials Science,
Biomaterials Center was started in October 2001,
aiming to realize a society with advanced
medicine. At the center, extensive and
comprehensive research and development
activities on biomater ials are conducted.
Application of polymer micelle to targeting to
cancer and to gene therapy and that of ceramic
materials to regenerative treatment are conducted
for DDS. At present, they collaborate with 20
engineering departments of universities (including
4 foreign universities), 15 medical departments of
universities (2 foreign) and 15 companies (2
foreign), aiming to be the main foothold of
research and development of biomaterials in
Japan[12].
6.6 Picture of DDS in the future
What is desired for the future DDS is to control
the drug transfer and reaction within the living
body according to a patient’s individual
differences, i.e., what amount, what speed, and
where and how the drug is released. For example,
in the treatment of diabetes, as stated above, it is
necessary to release insulin according to the
glucose concentration in the blood. The system
shown in Figure 10 is an ideal drug controlled
release system. To realize this system, the system
must have the following functions.
(1) Sensing function for the therapeutic effect
and drug concentration (Sensor development)
(2) Function for data processing and setting
release patterns (Data processing
development)
(3) Precision release function based on the above
setting (Precision release device
development)
It is also required for materials to have reliability
and safety to keep functions (1) to (3).
Not only research and development of material
sciences such as polymer and ceramic materials to
be combined with drug, but also the development
of sensing function, microanalysis, and precision
machine engineering are important.The following
research and development may be suggested.
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Figure 10: Ideal drug controlled release system
• Development of nanomachine for targeting
DDS, which has a drug-release control valve
driven by the morphological change of
molecule. It may be enabled by the modifica-
tion of liposome and polymer micelle with
nanomachine utilizing the morphological
change of nano-structural molecule, drugs, and
proteins having a sensing function.
• Research and development of a drug releasing
MEMS associated with the sensing function,
data processing, and precision release device.
6.7 Present status of 
examination of DDS
products
The “examination of DDS products” in the
Ministry of Health, Labour and Welfare is not
considered very much. The present status of the
“examination of DDS products” is as the
following[13].
• According to the notification from the Director
General in April 1999, regulations concerning
new active ingredients, new compounding
ingredients, new route of administration, new
virtues, new dosage form, and new dosage are
provided, but there is no peculiar regulations
corresponding to DDS products.
• In the regulation for the new dosage form
which is considered to be most related to DDS
products, toxicity tests, and efficacy
pharmacology and general pharmacology tests
are not necessary. However, those tests are
necessary for DDS products that provide
significant efficacy owing to excellent ideas
and technology.
• In the case of DDS products secondly put on
the market, even if the ingredients are different
from the advanced product, it is examined and
permitted in the same way of conventional
drugs.
• The guidelines for the examination of
sustained-release drugs were publicized in
1988, but the revision of the guidelines is not
conducted.
Therefore, the Japan Society of Drug Delivery
System submitted the “draft guidelines for the
examination of DDS products” to the Ministry of
Health and Welfare in July 1999. The guidelines
suggests that the characteristics of DDS products
should be understood well, logically necessary
basic and clinical tests should be sufficiently
conducted, and unnecessary ones should be
omitted to shorten the examination period[13].
An actual problem is that the period of
examination of pharmaceutical manufacturer in
our country is so long that the drugs are
sometimes re-imported after receiving permission
in the United States and European countries. The
long duration for the examination of new drugs in
Japan delays the practical use of drugs, that is
likely to be one of the causes for the lower
competitiveness of the medical industry of Japan
than that of the United States and Europe.
6.8 Conclusion
In the case of sustained-released type DDS,
almost all of the products with less difficulties in
the development are already introduced and put
into practical use. In the case of targeting DDS to
cancer cells that was stagnant, its development
rapidly progressed and the results came to be
applied clinically. In the field of regenerative
treatment and gene therapy, not only gene but also
cells are recognized as a drug, and a system to
carry this to the targeted affected site is
demanded. Moreover, MEMS being able to be used
as a DDS for the gastrointestinal system was
developed. Under these circumstances, projects
for DDS were taken up and proceeded in the
research project of the science and technology
policy (Nanomedicine project to apply nanotech
to medicine) of the Ministry of Health, Labour and
Welfare, and in the Core Research for Evaluational
Science and Technology of the Japan Science and
Technology Corporation. In addition, in the “New
industry created by nanotech” — n-Plan 2002—
published in November 2002, Nippon Keidanren
proposed that in order to maintain Japanese
technological competitiveness being high in the
field of nanomedicine, which is expected to
develop in the future, the government should head
the frontline of the research and development in
the nanomedicine field and tackle the
arrangement such as review and rapid operation
64
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
65
Q U A R T E R L Y  R E V I E W  N o . 7  /  A p r i l  2 0 0 3
of the medicine-related system, as well as close
cooperation between medical and engineering
fields.
The research and development of DDS is an
interdisciplinary area, and requires close
cooperation among medical science, pharmacy,
material science, bioengineering, precision
mechanical engineering, electronics, computer
and information science and so on. The
achievement of cooperation among such wide
fields cannot be expected by the effort of only one
corporation, one university, or one institute.
Therefore, followings are necessary to maintain
and raise the level of Japan’s high technological
competitiveness. Constructing an organization to
play a key role in the cooperation under the
strong leadership of the government as soon as
possible, gathering highly competent researchers,
arrangement of an environment and system, and
advancing the research and development of DDS
by a joint industry-university-government project.
Under the circumstance, the “Biotechnology
Strategy Meeting” proposal of fundamental
principles suggested the increase in funds of
bioresearch (double in 5 years) and the relief of
regulations including the reduction of the period
for the examination of new drugs.This proposal is
an important policy to promote the research and
development of DDS.
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